Author: ian@audiencemarketing.com

Isracann Biosciences Provides Bi-Weekly Default Status Report

VANCOUVER, BC, — (October 13, 2022) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) announces that further to its news release dated September 29, 2022 (the “Default Announcement”), the Company’s principal regulator, the British Columbia Securities Commission (the “BCSC”) granted a management cease trade order (the “MCTO”) on September 29, 2022,...
/ Corporate News
Read More

Isracann Biosciences Announces Delay in Filing Annual Financial Statements

VANCOUVER, BC, — (September 29, 2022) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) announces that the filing of its audited annual financial statements for the year ended May 31, 2022, including the related management discussion and analysis, and CEO and CFO certifications (collectively, the “Annual Financial Filings”) were not filed...
/ Corporate News
Read More

Isracann Bioscience Facilitated Genetics Arrive in Israel

Partner Facility Now Growing Canadian Cannabis Strains VANCOUVER, BC, — (September 28, 2022) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted Israel-based company focused on becoming a premier low cost, high quality cannabis producer/distributor is pleased to announce that previously shipped genetics have cleared Israeli customs and are being raised...
/ Corporate News
Read More

Isracann Biosciences Subsidiary Praesidio Health Submits NPNs to Health Canada

VANCOUVER, BC, — (May 19, 2022) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) a multi-faceted organization with a natural health medicine division in Canada and holdings in Israel, is pleased to announce that its wholly owned subsidiary Praesidio Health has completed the natural product number (NPN) submissions to Health Canada for...
/ Corporate News
Read More

Isracann Biosciences Renews Leadership to Meet Changing Demands

VANCOUVER, BC, — (April 15, 2022) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that further to it’s acquisition of Praesidio Health Inc. as a natural health medicine division, the Company has elected to expand its leadership team effective immediately. As Isracann moves from development to operations, and...
/ Corporate News
Read More

Isracann Biosciences Acquires Natural Health Medicine Developer and Appoints Natural Health Products Officers

VANCOUVER, BC, — (April 13, 2022) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news releases dated February 23, 2022 and March 28, 2022, it has closed its acquisition of Praesidio Health Inc. (“Praesidio”). Pursuant to the definitive agreement dated March 24, 2022...
/ Corporate News
Read More

Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer

VANCOUVER, BC, — (March 28, 2022) – Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news release dated February 23, 2022, it has entered into a definitive agreement (the “Agreement”) dated March 24, 2022 with Praesidio Health Inc. (“Praesidio”). Pursuant to the Agreement, the...
/ Corporate News
Read More

UPDATE – Isracann Signs LOI to Acquire Natural Health Medicine Developer

VANCOUVER, British Columbia, Feb. 24, 2022 — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company” or “Isracann”) a biosciences company focused on researching and developing innovative health solutions in conjunction with its advanced stage activities aimed at becoming a premier low-cost, high-quality cannabis producer/distributor is pleased to announce that on February 16,...
/ Global Cannabis News
Read More
Contact Us